Research on disease, treatment, and what keeps people well. Coverage runs from lab findings and clinical trials to public health, nutrition, and the health care system.
Nearly 20 percent of veterans have used acid, a rate that survives every demographic control, in RAND’s first nationally representative survey — which also finds roughly half don’t know whether disclosing use could cost them their VA benefits.
Rejections rose 67 percent over six years. After a denial, almost half of patients received no drug in the same therapeutic class within 90 days.
A preclinical DNA shot turned mouse muscle into a long-lasting GLP-1 source, outperforming daily semaglutide in early tests.
A NIST study found home gut microbiome tests can give conflicting answers from the same sample. The problem may lie in the tests themselves.
Engineered macrophages struggle to expand and persist as cancer therapies. USC researchers found a way to grow their upstream progenitors on a massive scale by blocking one enzyme. CAR-engineered versions attacked leukemia and solid tumors in mice. A new receptor design even recruited the host’s immune system across mismatch barriers.
A large Australian study finds that variants in the AQP4 gene are linked to memory and brain structure in older adults at risk for Alzheimer’s. Sleep quality shaped these effects. Poor sleep worsened brain atrophy and cognitive decline in certain genotypes. The findings point to sleep as a possible way to reduce genetic risk.
A new KFF Health Tracking Poll finds 41% of U.S. adults back the MAHA movement, and its food-safety and pesticide concerns resonate broadly. But even among MAHA voters, health care costs far outrank vaccines and food policy as the top priority heading into the 2026 midterms, reshaping how the movement may sway elections.